Evidence map›Paper›PMID 39849512›Full record

ReviewHereditary cancer in clinical practice2025

Colorectal carcinogenesis in the Lynch syndromes and familial adenomatous polyposis: trigger events and downstream consequences.

Pål Møller, Aysel Ahadova, Matthias Kloor, Toni T Seppälä, John Burn, Saskia Haupt, Finlay Macrae, Mev Dominguez-Valentin, Gabriela Möslein, Annika Lindblom and 8 more

Abstract readReview
In one paragraph

Review in Hereditary cancer in clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Pål MøllerDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital Oslo University Hospital, 0379, Oslo, Norway. moller.pal@gmail.com.
Aysel AhadovaDepartment of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Matthias KloorDepartment of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Toni T SeppäläFaculty of Medicine and Health Technology, Tays Cancer Centre, Applied Tumor Genomics Research Program, Research Programs Unit, Tampere University, Tampere University Hospital, University of Helsinki, Helsinki, Finland.
John BurnFaculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, NE1 7RU, UK.
Saskia HauptDepartment of Applied Tumour Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Finlay MacraeColorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Australia.
Mev Dominguez-ValentinDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital Oslo University Hospital, 0379, Oslo, Norway.
Gabriela MösleinSurgical Center for Hereditary Tumors, University Witten-Herdecke, Ev. Bethesda Khs Duisburg, Herdecke, Germany.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 171 76, Sweden.
Lone SundeDepartment of Clinical Genetics and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, 9000, Denmark.
Ingrid WinshipGenomic Medicine, The Royal Melbourne Hospital, Melbourne, Australia.
Gabriel CapellaHereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L; Hospitalet de Llobregat, Barcelona, 08908, Spain.
Kevin MonahanCentre for Familial Intestinal Caner, Lynch Syndrome & Family Cancer Clinic, St Mark's Hospital, London, UK.
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Vic, Australia.
D Gareth EvansManchester Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK.
Eivind HovigDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital Oslo University Hospital, 0379, Oslo, Norway.
Julian R SampsonDivision of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK. Sampson@cardiff.ac.uk.

Funding

Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Manchester National Institute for Health Research (NIHR) Biomedical Research Centre IS-BRC-1215-20007NCI NIH HHS U01 CA167551
6 · The paper itself

Abstract

Carcinogenesis encompasses processes that lead to increased mutation rates, enhanced cellular division (tumour growth), and invasive growth. Colorectal cancer (CRC) carcinogenesis in carriers of pathogenic APC (path_APC) and pathogenic mismatch repair gene (path_MMR) variants is initiated by a second hit affecting the corresponding wild-type allele. In path_APC carriers, second hits result in the development of multiple adenomas, with CRC typically emerging after an additional 20 years. In path_MLH1 and path_MSH2 carriers, second hits lead to the formation of microscopically detectable, microsatellite unstable (MSI) crypts, from which CRC develops in about half of carriers over their lifetime, often without progressing through a diagnosable adenoma stage. These divergent outcomes reflect the distinct functions of. the APC and MMR genes. In path_MLH1 and path_MSH2 carriers, a direct consequence of stochastic mutations may be the occurrence of invasive growth before tumour expansion, challenging the paradigm that an invasive cancer must always have an non-invasive precursor. In contrast to other path_ MMR carriers, path_PMS2 carriers who receive colonoscopic surveillance exhibit minimal increase in CRC incidence. This is consistent with a hybrid model: the initial mutation may cause an adenoma, and the second hit in the wild-type PMS2 allele may drive the adenoma towards become cancerous with MSI. Since all mutational events are stochastic, interventions aimed at preventing or curing cancer should ideally target the initial mutational events. Interventions focused on downstream events are external factors that influence which tumour clones survive Darwinian selection. In Lynch Syndrome, surveillance colonoscopy to remove adenomas may select for carcinogenetic pathways that bypass the adenoma stage.

Indexed as

APCCancerCarcinogenesisColonoscopyColorectalFamilial adenomatous polyposisFAPInheritedLSLynch syndromesMSH2MSH6MSIPMS2

Identifiers

PMID39849512
PMCPMC11755794

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.